Wealth Enhancement Advisory Services LLC Has $3.05 Million Position in Sanofi (NASDAQ:SNY)

Wealth Enhancement Advisory Services LLC lowered its holdings in Sanofi (NASDAQ:SNY) by 20.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 52,973 shares of the company’s stock after selling 13,509 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Sanofi were worth $3,053,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of SNY. Manning & Napier Advisors LLC bought a new stake in shares of Sanofi during the 2nd quarter worth $13,725,000. Mount Yale Investment Advisors LLC raised its stake in shares of Sanofi by 44.3% during the 1st quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock worth $2,027,000 after purchasing an additional 12,806 shares during the period. Jennison Associates LLC raised its stake in shares of Sanofi by 18.9% during the 1st quarter. Jennison Associates LLC now owns 189,622 shares of the company’s stock worth $9,216,000 after purchasing an additional 30,115 shares during the period. Sei Investments Co. raised its stake in shares of Sanofi by 9.3% during the 1st quarter. Sei Investments Co. now owns 554,028 shares of the company’s stock worth $26,926,000 after purchasing an additional 47,297 shares during the period. Finally, Janney Montgomery Scott LLC raised its stake in shares of Sanofi by 10.4% during the 1st quarter. Janney Montgomery Scott LLC now owns 307,627 shares of the company’s stock worth $14,951,000 after purchasing an additional 29,082 shares during the period. Institutional investors and hedge funds own 10.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on SNY shares. StockNews.com upgraded Sanofi from a “buy” rating to a “strong-buy” rating in a research note on Wednesday. Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Finally, Argus boosted their price objective on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi currently has an average rating of “Buy” and a consensus target price of $57.50.

Sanofi Trading Up 0.7 %

Shares of SNY opened at $53.27 on Friday. The business’s 50-day moving average price is $55.92 and its 200-day moving average price is $51.96. Sanofi has a twelve month low of $45.00 and a twelve month high of $58.97. The stock has a market cap of $135.19 billion, a PE ratio of 27.18, a P/E/G ratio of 1.36 and a beta of 0.60. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same period in the prior year, the business posted $2.55 earnings per share. The company’s revenue was up 12.3% on a year-over-year basis. On average, equities analysts forecast that Sanofi will post 4.27 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.